Payment overview · 2025
General Payments
$459.96
24 reported records · 16 companies
Healthcare provider profile · identity verified
Patrick Michael Mcgowan, M.D. MPH
Allopathic & Osteopathic Physicians|Family Medicine · SPRINGDALE, AR · NPI 1730569310
Verified facts
What the public records show
CMS Open Payments records show Patrick Michael Mcgowan, M.D. MPH received $459.96 in general payments during 2025 across 24 reported records.
PFIZER INC. accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $97.95 | 21.3% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $73.11 | 15.9% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $36.32 | 7.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.43 | 7.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.35 | 5.3% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $23.63 | 5.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.64 | 4.5% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $20.02 | 4.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.10 | 4.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.36 | 4.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.78 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.56 | 3.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.52 | 3.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.40 | 3.4% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $14.87 | 3.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.92 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $459.96 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $73.11 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $57.85 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.10 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.10 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.10 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.43 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 88 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 121 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
121 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 445 | 125 |
| Omeprazole | Omeprazole | 350 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 334 | 82 |
| Lisinopril | Lisinopril | 324 | 92 |
| Losartan Potassium | Losartan Potassium | 288 | 80 |
| Trazodone Hcl | Trazodone Hcl | 229 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 226 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 63 |
| Meloxicam | Meloxicam | 201 | 75 |
| Metformin Hcl | Metformin Hcl | 193 | 55 |
| Gabapentin | Gabapentin | 186 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 43 |
| Tramadol Hcl | Tramadol Hcl | 143 | 48 |
| Ozempic | Semaglutide | 121 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 39 |
| Simvastatin | Simvastatin | 110 | 27 |
| Furosemide | Furosemide | 104 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 99 | 37 |
| Atenolol | Atenolol | 91 | 28 |
| Famotidine | Famotidine | 89 | 23 |
| Eliquis | Apixaban | 88 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 78 | 73 |
| Montelukast Sodium | Montelukast Sodium | 78 | 22 |
| Carvedilol | Carvedilol | 77 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 77 | 58 |
| Prednisone | Prednisone | 76 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 18 |
| Potassium Chloride | Potassium Chloride | 73 | 17 |
| Sertraline Hcl | Sertraline Hcl | 73 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 19 |
| Allopurinol | Allopurinol | 58 | 12 |
| Benazepril Hcl | Benazepril Hcl | 58 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 14 |
| Azithromycin | Azithromycin | 55 | 51 |
| Estradiol | Estradiol | 54 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 13 |
| Glipizide | Glipizide | 51 | 13 |
| Spironolactone | Spironolactone | 51 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 19 |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 35 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 41 | 13 |
| Celecoxib | Celecoxib | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | 11 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Alprazolam | Alprazolam | 33 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | 13 |
| Meclizine Hcl | Meclizine Hcl | 26 | 14 |
| Finasteride | Finasteride | 25 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Lorazepam | Lorazepam | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Jardiance | Empagliflozin | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $459.96 · 24 records | PFIZER INC. | ABRYSVO, BREZTRI, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, GARDASIL 9, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, PROLIA, Rybelsus, SKYCLARYS, VAXNEUVANCE, VOQUEZNA, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error